BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12626499)

  • 1. Specific amino acid substitutions determine the differential contribution of the N- and C-terminal domains of insulin-like growth factor (IGF)-binding protein-5 in binding IGF-I.
    Shand JH; Beattie J; Song H; Phillips K; Kelly SM; Flint DJ; Allan GJ
    J Biol Chem; 2003 May; 278(20):17859-66. PubMed ID: 12626499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cumulative mutagenesis of the basic residues in the 201-218 region of insulin-like growth factor (IGF)-binding protein-5 results in progressive loss of both IGF-I binding and inhibition of IGF-I biological action.
    Allan GJ; Tonner E; Szymanowska M; Shand JH; Kelly SM; Phillips K; Clegg RA; Gow IF; Beattie J; Flint DJ
    Endocrinology; 2006 Jan; 147(1):338-49. PubMed ID: 16195401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acids within the extracellular matrix (ECM) binding region (201-218) of rat insulin-like growth factor binding protein (IGFBP)-5 are important determinants in binding IGF-I.
    Bramani S; Song H; Beattie J; Tonner E; Flint DJ; Allan GJ
    J Mol Endocrinol; 1999 Aug; 23(1):117-23. PubMed ID: 10425523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation.
    Yan X; Forbes BE; McNeil KA; Baxter RC; Firth SM
    J Biol Chem; 2004 Dec; 279(51):53232-40. PubMed ID: 15485880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin.
    Arai T; Clarke J; Parker A; Busby W; Nam T; Clemmons DR
    J Biol Chem; 1996 Mar; 271(11):6099-106. PubMed ID: 8626396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions.
    Imai Y; Moralez A; Andag U; Clarke JB; Busby WH; Clemmons DR
    J Biol Chem; 2000 Jun; 275(24):18188-94. PubMed ID: 10766744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlap of IGF- and heparin-binding sites in rat IGF-binding protein-5.
    Song H; Beattie J; Campbell IW; Allan GJ
    J Mol Endocrinol; 2000 Feb; 24(1):43-51. PubMed ID: 10656996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation.
    Fowlkes JL; Thrailkill KM; George-Nascimento C; Rosenberg CK; Serra DM
    Endocrinology; 1997 Jun; 138(6):2280-5. PubMed ID: 9165012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The carboxy-terminal domain of IGF-binding protein-5 inhibits heparin binding to a site in the central domain.
    Song H; Shand JH; Beattie J; Flint DJ; Allan GJ
    J Mol Endocrinol; 2001 Jun; 26(3):229-39. PubMed ID: 11357059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF-binding proteins.
    Hsieh T; Gordon RE; Clemmons DR; Busby WH; Duan C
    J Biol Chem; 2003 Oct; 278(44):42886-92. PubMed ID: 12917428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin.
    Sorrell AM; Shand JH; Tonner E; Gamberoni M; Accorsi PA; Beattie J; Allan GJ; Flint DJ
    J Biol Chem; 2006 Apr; 281(16):10883-9. PubMed ID: 16505491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural changes in insulin-like growth factor (IGF) I mutant proteins affecting binding kinetic rates to IGF binding protein 1 and IGF-I receptor.
    Jansson M; Uhlen M; Nilsson B
    Biochemistry; 1997 Apr; 36(14):4108-17. PubMed ID: 9100004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor (IGF)-binding protein-5-(201-218) region regulates hydroxyapatite and IGF-I binding.
    Campbell PG; Andress DL
    Am J Physiol; 1997 Nov; 273(5):E1005-13. PubMed ID: 9374688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular recognition characteristics in the insulin-like growth factor (IGF)-insulin-like growth factor binding protein -3/5 (IGFBP-3/5) heparin axis.
    Beattie J; Phillips K; Shand JH; Szymanowska M; Flint DJ; Allan GJ
    J Mol Endocrinol; 2005 Feb; 34(1):163-75. PubMed ID: 15691886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth.
    Nam TJ; Busby WH; Rees C; Clemmons DR
    Endocrinology; 2000 Mar; 141(3):1100-6. PubMed ID: 10698186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I.
    Parker A; Rees C; Clarke J; Busby WH; Clemmons DR
    Mol Biol Cell; 1998 Sep; 9(9):2383-92. PubMed ID: 9725901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperativity of the N- and C-terminal domains of insulin-like growth factor (IGF) binding protein 2 in IGF binding.
    Kuang Z; Yao S; McNeil KA; Thompson JA; Bach LA; Forbes BE; Wallace JC; Norton RS
    Biochemistry; 2007 Dec; 46(48):13720-32. PubMed ID: 17985932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs.
    Oh Y; Müller HL; Lee DY; Fielder PJ; Rosenfeld RG
    Endocrinology; 1993 Mar; 132(3):1337-44. PubMed ID: 7679979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions.
    Kalus W; Zweckstetter M; Renner C; Sanchez Y; Georgescu J; Grol M; Demuth D; Schumacher R; Dony C; Lang K; Holak TA
    EMBO J; 1998 Nov; 17(22):6558-72. PubMed ID: 9822601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding properties of insulin-like growth factor binding protein-3 (IGFBP-3), IGFBP-3 N- and C-terminal fragments, and structurally related proteins mac25 and connective tissue growth factor measured using a biosensor.
    Vorwerk P; Hohmann B; Oh Y; Rosenfeld RG; Shymko RM
    Endocrinology; 2002 May; 143(5):1677-85. PubMed ID: 11956149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.